RAPT Therapeutics(US:RAPT)2025-03-06 13:05Financial Performance - Net loss for Q4 2024 was $53.2 million, an increase of 72.1% compared to a net loss of $30.9 million in Q4 2023[3] - For the full year 2024, net loss was $129.9 million, compared to $116.8 million for 2023, reflecting a 11.5% increase[8] Research and Development - Research and development expenses for Q4 2024 were $46.5 million, up 73.8% from $26.8 million in Q4 2023, primarily due to a $35.0 million upfront license fee for RPT904[4] - Total research and development expenses for 2024 were $107.2 million, a 6.3% increase from $101.0 million in 2023[9] - RPT Therapeutics plans to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025[2] Operating Expenses - General and administrative expenses for Q4 2024 were $8.0 million, a 23.1% increase from $6.5 million in Q4 2023[5] - The company reported total operating expenses of $54.5 million for Q4 2024, compared to $33.2 million in Q4 2023, marking a 63.8% increase[15] Cash and Financing - The company had cash and cash equivalents and marketable securities of $231.1 million as of December 31, 2024[11] - The company raised $143.0 million through a private placement of 100 million shares at $0.85 per share in December 2024[7] - In December 2024, the company entered a license agreement for RPT904, paying a $35.0 million upfront fee and potential milestone payments up to $672.5 million[6]